Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

  • bioRxiv. 2021 Aug 10;2021.08.06.455494. doi: 10.1101/2021.08.06.455494.
Michael K Lo  1 ,  Punya Shrivastava-Ranjan  1 ,  Payel Chatterjee  1 ,  Mike Flint  1 ,  James R Beadle  2 ,  Nadejda Valiaeva  2 ,  Robert T Schooley  2 ,  Karl Y Hostetler  2 ,  Joel M Montgomery  1 ,  Christina Spiropoulou  1
Affiliations
  • 1. Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia, USA.
  • 2. Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA.
PMID: 34401879 DOI: 10.1101/2021.08.06.455494
Abstract

The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum Antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater Antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.

Products